Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy
DE Kohan, Y Pritchett, M Molitch, S Wen… - Journal of the …, 2011 - journals.lww.com
Although endothelin-receptor antagonists reduce albuminuria in diabetic nephropathy, fluid
retention limits their use. Here, we examined the effect of atrasentan, a selective endothelin
A receptor (ET AR) antagonist, on albuminuria in a randomized, double-blind, placebo-
controlled trial of subjects with diabetic nephropathy already receiving stable doses of renin-
angiotensin system (RAS) inhibitors. We randomly assigned 89 subjects with eGFR> 20
ml/min per 1.73 m 2 and a urinary albumin-to-creatinine ratio (UACR) of 100 to 3000 mg/g to …
retention limits their use. Here, we examined the effect of atrasentan, a selective endothelin
A receptor (ET AR) antagonist, on albuminuria in a randomized, double-blind, placebo-
controlled trial of subjects with diabetic nephropathy already receiving stable doses of renin-
angiotensin system (RAS) inhibitors. We randomly assigned 89 subjects with eGFR> 20
ml/min per 1.73 m 2 and a urinary albumin-to-creatinine ratio (UACR) of 100 to 3000 mg/g to …